Ryan Rountree

Ryan Rountree is an accomplished professional in preclinical pharmacology, currently serving as Executive Director of Preclinical Pharmacology at Nurix Therapeutics since March 2021, where responsibilities include leading efforts to develop novel oncology and immuno-oncology therapeutics targeting E3 ubiquitin ligases and managing an in vivo pipeline for profiling compounds. With a progressive career at Nurix Therapeutics since 2016 that includes prior roles as Senior Director and Director, Rountree has extensive experience in developing genetic mutant models and managing cross-departmental activities in immunotherapy. Previous experience includes significant roles at Bavarian Nordic, where project management and BLA documentation were critical for immunotherapy products, and consulting roles at Krypton Immuno-Oncology. Educational credentials include a Ph.D. in Developmental Biology from Stanford University School of Medicine and a B.S. in Genetics from the University of California, Davis.